Monthly Archives: August 2011

Raising the Stakes in Biotech

JimGreenwood

Small biotech companies continue to struggle to obtain funding as capital markets remain tight. The S&P downgrade may create even tighter credit markets and raise the cost of available credit, for small and large companies. To the extent that the downgrade leads capital flows out of the U.S., that hurts biotech. Biotech’s contributions to the world are critically needed. Our industry holds great promise for curing and treating many prevalent diseases, such as Alzheimer’s, cancer, Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

When RARE is not so RARE!

Nicole Boice

By Nicole Boice, Founder/President, RARE Project Did you know that there is a community of sick and disabled women, children, and men that is so large that it outnumbers all of those with cancer and AIDS combined worldwide?  Scary to think about? Can you guess what it is? Staggering Statistics The Rare Disease Community is made up of over 7,000 known rare diseases and over 350 million people worldwide.  Here in the US, over 35 Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , ,

State Legislator Profile: Washington State Rep. John McCoy

Washington State Rep. John McCoy (D-Tulalip)

If you ask most people to name a few things about the state of Washington, the word technology is likely to wind up somewhere in the mix. However, the birthplace of Microsoft and Amazon.com is also a biotech heavyweight. Washington contains one of the world’s largest life sciences clusters and is home to dozens of research institutes and some of the nation’s leading public research universities. The biotech industry in Washington employs tens of thousands Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , ,

BioCentury TV at BIO International Convention

marq_080711_play

BioCentury TV interviewed biotech leaders throughout the recent BIO International Convention in Washington, DC. The first interview can be found here (links to the other interviews can be found on the right). (July 24) Public+Private Part 1 — Turning Great Science into Medicine — and Jobs: Dr. Michel Goldman of Europe’s Innovative Medicines Initiative xplains how the pharma-driven agenda is creating a new “ecosystem” in Europe for drug developers. (July 31) Public+Private Part 2 – Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotechnology Patenting in Europe Event

2390666040_2e6b0a9a78_m

BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States.  Most of this cost is mainly due to language translation requirements and renewal fees.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,